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Current therapeutics in autism spectrum disorders (ASD) only treat the associated symp-
toms, without addressing core social dysfunctions. A paradigm shift in research of the
pathogenesis of ASD, its synaptic abnormalities and altered signaling in multiple dynamic
systems, have led to new experimental treatments for treating the core social abnormalities
of ASD. NMDA antagonists, especially memantine, have been introduced in clinical trials
addressing glutamatergic transmission in children and adolescents with ASD. GABAergic
signaling has been targeted in trials using the GABAB receptor agonist arbaclofen for ASD
patients with promising results. Oxytocin has been recognized as implicated in social devel-
opment and affiliative behaviors. Preliminary findings from clinical trials using oxytocin in
children with ASD show encouraging improvements in social cognition, but larger studies
are needed. In two of the single gene disorders associated with ASD, Insulin Growth Factor
(IGF-1) is a new treatment that has been tested in Rett syndrome and Phelan-McDermid
syndrome (Chromosome 22 deletion syndrome). IGF-1 has been demonstrated to reverse
the reduction in the number of excitatory synapses and the density of neurons that char-
acterize these conditions in animal studies and it is being introduced as an experimental
treatment. As a novel approach to verify treatment efficacy, neural processing modifica-
tions were recently evaluated by fMRI after a pivotal response training intervention. Another
study of neural changes in response to treatment examined variations in EEG signaling in
patients after an Early Start Denver Model (ESDM) intervention.
Keywords: autism spectrum disorders, experimental treatments, preclinical models, clinical trials, childhood and
adolescence
INTRODUCTION
Autism spectrum disorders (ASD) are early-onset neurodevel-
opmental disorders characterized by major difficulties in social
interaction, communication, and repetitive or restricted interests
and behaviors. Autism is defined as a spectrum disorder due to
the heterogeneity of clinical presentation, the degree of social
impairment, intellectual ability, associated symptoms,and possible
etiology. ASD are included in the diagnostic category of neurode-
velopmental disorders in the Diagnostic and Statistical Manual of
Mental Disorders V (1). The diagnosis of ASD is based on two
major symptoms: social-communication deficits, restricted and
repetitive interests, and behaviors. By definition, these symptoms
must occur during the early childhood of individuals with ASD.
The currently accepted prevalence of ASD, based on consistent
reports from multiple sources in different populations, is about 1%
worldwide. ASDs are therefore among the most common perva-
sive developmental disorders and there is great concern regarding
its growing incidence (2–4).
To date, the only FDA-approved treatments for ASD are the
atypical antipsychotics risperidone and aripiprazole, which are
mainly directed at treating the associated symptoms and not
the core social dysfunctions that characterize this heterogeneous
group of disorders. Treatments with these two medications have
been demonstrated to reduce and attenuate irritability (e.g.,
tantrums, aggression, hyperactivity, and self-injurious behaviors)
in children and adolescents with ASD (5–8). Improvements in
social interaction and reciprocity have been observed as well, but
this is probably a secondary effect of an overall reduction in mal-
adaptive behaviors and not a primary therapeutic effect of these
medications.
Targeted treatments for ASD are developed through the under-
standing of molecular and cellular abnormalities that guide spe-
cific interventions, hypothesizing that the wide variety of genetic
variants in ASD converge in a core set of molecular pathways
that mediate phenotypic expression in some identifiable core
symptoms (9). Most research for new therapeutics currently uses
preclinical models, such as “knockout” mice displaying specific
molecular abnormalities. Genetic studies of ASD and related neu-
rodevelopmental disorders have provided classes of potentially
useful compounds. Proof-of-principle assays with agents that
reversed phenotypes in mouse models have paved the way for
clinical trials (10).
EXCITATORY/INHIBITORY IMBALANCE IN ASD AND NEW
TREATMENTS
An imbalance of excitatory (glutamate) to inhibitory (GABA) neu-
rotransmission (E/I imbalance) is thought to be implicated in the
pathogenesis of ASD (11–13). Excessive excitatory glutamatergic
neurotransmission with a loss of inhibitory GABA transmission,
as well as abnormalities in synaptic plasticity due to dysfunctions
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in the NMDA, AMPA, and/or GABA receptor systems, have been
detected in mouse models and support this conceptualization of
ASD pathogenesis (10). Pharmacological evidence emerged from
mouse models with deletions in synaptic genes Fmr1, Mecp2,
and Shank2, and the BTBR inbred strain, which have demon-
strated favorable outcomes from treatments with glutamatergic
agents, including memantine (14). After these preclinical investi-
gations, clinical trials were carried out to test the potential role
of glutamatergic and GABAergic agents in reversing core social
dysfunction in ASD.
GLUTAMATERGIC TARGETING IN ASD
Altered glutamatergic excitatory transmission involves differ-
ent receptors, including down-regulation of AMPA receptors,
abnormalities of NMDA receptor-mediated plasticity, and altered
metabotropic glutamate receptor subtype 5(mGluR5) signal
transduction. The mGluR5 antagonists have been tested in preclin-
ical models of autism with variable effects on social and stereotypic
behaviors (15). MPEP, an antagonist of the mGluR5 receptor,
reduced repetitive self-grooming in BTBR mice. BTBR is an autism
mouse model with behavioral abnormalities in social interaction
and communication, as well as repetitive movements and behav-
iors. Risperidone also reduced repetitive self-grooming in BTBR,
but only at doses that induced sedation (16). GRN-259, a selec-
tive negative allosteric modulator of the mGluR5 receptor, was
tested in BTBR mice. GRN-529 reduced repetitive behaviors in
three cohorts of BTBR mice and it attenuated social withdrawal
with an associated increase in communication, providing overall
improvement in behavioral conditions (17). Treatment with the
two AMPAKINE compounds CX1837 and CX1739, agents active
on AMPA receptors that enhance excitatory glutamatergic action,
succeeded in recovering social impairment but it did not attenuate
the high levels of repetitive self-grooming in BTBR (18). In 4-
week-old Balb/c mice, the NMDA receptor agonist d-cycloserine
was found to improve both sociability and repetitive behaviors,
emphasizing the potential role of NMDA agents in modulating
the core social dysfunctions of ASD (19). Studies of Shank3 het-
erozygous mice detected a reduction in basal neurotransmission,
reflecting reduced AMPA receptor-mediated transmission, which
was targeted with insulin growth factor (IGF-1) treatment (20, 21).
Clinical trials followed the preclinical phase of investigation
with glutamatergic agents. Memantine, an NMDA receptor antag-
onist, was tested in children and adolescents with ASD. Overall,
the memantine trials conducted so far have yielded inconsistent
findings due to methodological flaws, thus they did not allow for
firm conclusions. No recommendations on the use of memantine
or of other glutamatergic agents in ASD treatment are warranted
as yet (22).
GABAergic TARGETING IN ASD
GABAergic signaling has been demonstrated to be implicated
in E/I imbalance in ASD (23). Engrailed2 (En2) knockout mice
have been proposed as a model for ASD. In this mutant, the
cerebellum and hippocampus have been shown to have abnor-
mal synaptic transmission, altered developmental processes and
defective GABA transmission convergent with ASD pathways.
A link between altered function of En2, deficits of GABAergic
forebrain neurons, and the pathogenesis of ASD has been pos-
tulated (24, 25). In addition, social and cognitive abnormalities
have been detected in En2 knockout mice, further highlighting
its role in ASD. Deficits in reciprocal social interactions grow-
ing over time were found in En2 null mutants (26). Interestingly,
mice lacking Mecp2 from GABA-releasing neurons demonstrated
Rett syndrome and autistic features, including repetitive behav-
iors. In these mice, MeCP2-deficient GABAergic neurons showed
a presynaptic reduction in glutamic acid decarboxylase 1 (Gad1)
and glutamic acid decarboxylase 2 (Gad2) levels, and GABA
immunoreactivity (27).
In clinical trials, GABA signaling has been probed with spe-
cific compounds. Arbaclofen, a GABAB receptor agonist that acts
upstream of mGluR5 receptor signaling and is thought to aug-
ment inhibitory neurotransmission, was investigated. Initially, a
preclinical study (28) followed by a clinical trial with arbaclofen
was carried out in Fragile X syndrome, the most common cause
of intellectual disability and ASD (29), and favorable findings
were reported regarding social domains (30). A recent open-label
trial with STX209, a form of Arbaclofen, was conducted in ASD
patients (31). Safety, tolerability, and efficacy were tested in ASD
individuals in an 8-week open-label trial enrolling 32 children
and adolescents with a score of ≥17 on the aberrant behavior
checklist (ABC)-irritability subscale. STX209 was generally well
tolerated. Improvements were reported on several outcome mea-
sures, including the ABC-Irritability (the primary endpoint) and
the Lethargy/Social Withdrawal subscales, and the Social Respon-
siveness Scale. Randomized controlled trials are needed to confirm
these preliminary positive findings.
mTOR TARGETING IN ASD
The mammalian target of rapamycin (mTOR) pathway is cen-
tral to synaptic protein synthesis and it integrates inputs from
different sources, including NMDA and metabotropic glutamate
receptors. In addition, it is directly involved in the mainte-
nance of the physiological synaptic E/I ratio. Abnormalities in
mTOR signaling have been found in ASD (32). Activation of
mTORC1 promotes the formation of the eIF4F initiation com-
plex. Mutations in genes upstream of mTOR, as detected in
tuberous sclerosis complex (TSC1/2), neurofibromatosis 1(NF1),
phosphatase and tensin homolog (PTEN), or the Fragile X syn-
drome gene (FMR1) cause hyperactivity of the mTORC1–eIF4E
pathway and lead to syndromic forms of ASDs (33, 34). Accord-
ingly, mTOR inhibitors are first line candidates for the treatment
of ASD in TSC (35). Everolimus, an mTOR inhibitor, is cur-
rently being studied in a double-blind controlled trial in children
and adolescents (6–21 years old) with TSC, ASD and seizures
(NCT01289912).1 The primary aim of this trial is improve-
ment in cognition, while ASD symptoms attenuation and seizure
frequencies are secondary objectives. Rapamycin, an mTORC1
inhibitor and immune-suppressor, was investigated in a recent
preclinical study as an agent to ameliorate social behaviors and
attenuate stereotypies in BTBR mice. Rapamycin was found to
improve many components of sociability in the BTBR mouse,
1http://clinicaltrials.gov

























































Canitano New treatments of social domain in ASD
pointing to mTOR overactivation as a therapeutic target in ASD.
However, no effects of rapamycin on stereotypic behaviors were
detected (36).
An important regulatory action was recently described in the
other component of this pathway, the downstream effectors of
mTOR. Signaling molecules in the downstream of the mTOR
pathway have been demonstrated to play crucial roles in ASD
pathogenesis, further highlighting its role (37, 38). Furthermore,
4E-BP2 inhibits protein translation by competing with eIF4G
for eIF4E binding. The deletion of the gene encoding 4E-BP2
(EIF4ebp2) leads to autistic-like behaviors in mice. It was demon-
strated that the removal of 4E-BP2, or overexpression of eIF4E,
enhances protein translation; increased translation of neuroligins
(NLGNs) is the next step that in turn causes an increased synaptic
E/I ratio, which may eventually lead to ASD phenotypes. Pharma-
cological inhibition of eIF4E reversed social behavior deficits in
EIF4ebp2 knockout mice and restored the E/I balance (37). These
findings thus established a strong link between eIF4E-dependent
translational control of NLGNs, E/I balance, and the develop-
ment of ASD-like behaviors. Pharmacological targeting of down-
stream effectors of mTOR may represent promising experimental
therapeutics in ASDs.
SINGLE GENE DISORDERS WITH ASD AND EXPERIMENTAL
TREATMENTS
Single gene disorders associated with high rates of comorbid ASD,
such as Rett syndrome and Phelan-McDermid syndrome (PMS)
have provided significant models of targeted interventions with
novel experimental treatments.
IGF-1 IN PHELAN-McDERMID SYNDROME (CHROMOSOME 22q13
DELETION SYNDROME)
The loss of a functional copy of the SHANK3 gene leads to
22q13 deletion syndrome, a complex clinical condition known as
PMS. Haploinsufficiency of SHANK3 accounts for about 0.5%
of cases of ASD and/or developmental delay (39). There is
mounting evidence for a wider role of SHANK3 and glutamate
signaling abnormalities in ASD and related conditions. IGF-1
regulates synapse formation, neurotransmitter release, and neu-
ronal excitability via posttranslational modification of NMDA and
AMPA receptors (40).
Therapeutic approaches with IGF-1 aimed at reversing deficits
in SHANK3-haploinsufficiency have been carried out in mice.
IGF-1 has been demonstrated to reverse the reduction in exci-
tatory synapse numbers and density of neurons. Administration
of daily intraperitoneal injections of human IGF-1 over a 2-week
period was found to reverse deficits in hippocampal AMPA sig-
naling, long-term potentiation (LTP), and motor performance in
Shank3-deficient mice (41). These findings led to a current trial of
IGF-1 as a treatment in PMS, which is still underway and expected
to provide important clues on its role in the treatment of this ASD
subtype (see text footnote 1 NCT0152590).
In a recent study, induced pluripotent stem cells (iPSCs) from
individuals with PMS and autism were used to produce functional
neurons. It was demonstrated that PMS neurons have reduced
SHANK3 expression and major defects in excitatory, but not
inhibitory, synaptic transmission. IGF-1 treatment promoted the
formation of mature excitatory synapses that lack SHANK3 but
contain PSD95 and NMDA receptors with fast deactivation kinet-
ics. These findings provided evidence for a disruption in the ratio
of E/I in PMS neurons, and they point to a molecular pathway that
can be recruited to restore it (42).
IGF-1 IN RETT SYNDROME
Studies in mouse and human neuronal models of Rett syndrome
also demonstrated benefits with IGF-1 administration. In 90% of
cases, Rett syndrome is caused by abnormalities on the MECP2
gene, by either deletions or mutations. IGF-1, highly expressed
during brain development and very important for spine mat-
uration, has been tested to overcome MECP2 deficit. Synaptic
abnormalities have been observed in Rett syndrome related to
genetic defects on the MECP2 gene (43). Treatment with IGF-1
in a mouse model of Rett syndrome has been shown to increase
synaptic growth and to rescue phenotype defects (44). A phase II
randomized placebo-controlled trial is underway to evaluate the
safety and efficacy of IGF-1 in treating ASD symptoms and res-
piratory/autonomic dysfunction in patients with Rett syndrome
(see text footnote 1 NCT01777542).
INTRANASAL OXYTOCIN IN ASD
There has been growing interest in oxytocin as it is recognized
to be implicated in social development and affiliative behaviors.
Intranasal oxytocin has been shown to increase social initiative
and motivation (45), as well as social cognition (46), and to reduce
repetitive and restricted behaviors in ASD. Previous studies with
oxytocin in ASD were conducted by single-dose administration
to adults, therefore, the long-term effect of nasal oxytocin and its
effect on children must still be clarified (47).
There have been only a few trials with intranasal oxytocin in
children with ASD, and most were pilot studies on small num-
bers of patients. In one of the first double-blind studies, oxytocin
nasal spray was found to improve emotion recognition in 16
male youth aged 12–19 with ASD (48). In a recent pilot study,
15 children and adolescents with ASD with verbal IQs of ≥70
participated in a trial on the safety and tolerability of intranasal
oxytocin. Repeated measures of regression analysis controlled for
week, dose, age, and sex were employed. The highest dose eval-
uated, 0.4 IU/kg, was found to be well tolerated. Over 3 months
of treatment, social cognition, repetitive behaviors, and anxiety
were improved with the maintenance of effect for 3 months after
discontinuation of treatment (49). In an open-label study, oxy-
tocin was administered intranasaly over a long term of 7 months
to eight male youths with ASD (10–14 years of age; IQ: 20–101).
Six of the eight participants had improvement in the commu-
nication and social interaction domains at ADOS-G evaluation
and at T -scores of the CBCL; however, no statistically signifi-
cant improvement was found in the ABC (50). In a double-blind
study with a controlled design, a group of 38 male youths (7–
16 years old) with ASD were administered 24 or 12 IU, depending
on weight, of intranasal placebo or oxytocin once daily over four
consecutive days. The oxytocin or placebo was administered in
a dynamic social condition, i.e., during parent–child interaction
training sessions. In this study, intranasal oxytocin did not sig-
nificantly improve social interaction skills, however it must be
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mentioned that it was an untested behavioral intervention, limit-
ing the interpretation of results (51). Collectively, these studies
demonstrated mixed results as to the outcome of core social
impairment, with a tendency toward an improvement in social
domains. Large-scale, double-blind placebo-controlled studies are
needed to confirm the role of intranasal oxytocin in core social
ASD dysfunction.
A randomized, double-blind cross over fMRI trial with
intranasal oxytocin was conducted in a group of 17 ASD children
and adolescents (age 8–16.5 years) to evaluate neural circuit mod-
ifications hypothesized after oxytocin administration (52). The
Reading the Mind in the Eyes Test (RMET), a social cognition test
(53) was used to investigate the brain areas under examination,
and a remarkable variation was observed 45 min after oxytocin
administration. Structures and circuits within the so-called social
brain, such as the dorsal and ventral striatum, premotor cor-
tex, posterior cingulate, and posterior–superior temporal sulcus,
demonstrated enhanced activity after oxytocin administration.
Moreover, changes in salivary oxytocin concentrations from base-
line to 30 min post administration were positively associated with
increased activity in the right amygdala and orbito-frontal cor-
tex during social vs. non-social judgments. Furthermore, it was
highlighted that oxytocin enhanced the salience of social stimuli,
thus positively interfering with social cognition. These changes
in the relevant brain areas of interest were observed following a
single oxytocin administration and further research to test the
persistence of these changes over time in long-term treatments is
needed.
NEW APPROACHES TO VERIFY TREATMENT EFFICACY
Neural circuit modification following treatment for ASD is a novel
field of research that could shed light on the mechanisms involved
in neural changes and in the search for the biomarkers of treat-
ment response (54). Functional MRI is the main instrument for
a dynamic investigation of the neural substrate. A case study in
two children with ASD was carried out with functional MRI per-
formed before and after an intensive intervention of 4 months
of pivotal response training (PRT). PRT is an empirically vali-
dated behavioral treatment that has widespread positive effects
on communication, behavior, and social skills in young children
with ASD. Neural processing modifications during a biological
motion task, a form of social information, were evaluated by fMRI.
Outcome measures included the evaluation of dysfunctional areas
identified in children with ASD, compared to typically developing
children (right amygdala, bilateral fusiform gyri, left ventrolat-
eral prefrontal, and right posterior superotemporal sulcus). After
treatment, ASD children showed increased activation in the above
listed areas, indicating that neural modifications had occurred and
they overlapped with the brain area activations of their typically
developing peers (55).
Another study, investigating neural changes in response to
treatment, examined variations in EEG signaling after an interven-
tion with the Early Start Denver Model (ESDM) in a group of 48
children with ASD, aged 18–30 months. Children with ASD were
randomized into two groups; one received an ESDM intervention
for 2 years and the other received only their previous treatment in
the community. A typically developing group of children served
as controls. Event related potentials (ERP) and EEG activity (spec-
tral power) were detected during the presentation of faces versus
objects. The ESDM group demonstrated a better outcome in ASD
symptoms, IQ, language, and adaptive behavior than the others.
Increased cortical activation, i.e., a reduction in alfa power and
increased theta band, was detected in this group of children as
well as in typically developing children when viewing faces, in
contrast to the community intervention group that showed the
opposite pattern with greater cortical activation when viewing
objects. The limitation of this research was that it lacked a baseline
evaluation (56).
CONCLUSION AND FUTURE DIRECTIONS
Currently available medications mostly act upon selective symp-
toms of ASD, possibly offering a chance to further explore the
specific mechanisms and circuits involved in etiological factors.
Synaptic or circuit mechanisms associated with circumscribed
aspects of ASD, e.g., social and communication domains, need
to be thoroughly evaluated at the molecular and synaptic lev-
els and possibly separated from the other symptoms/domains.
Core mechanisms that cover distinct fractions of ASD would
parallel the concept of core symptoms in ASD, based on the
hypothesis that a group of protein factors converges on com-
mon pathways to be targeted (13). The next generation of ani-
mal models carrying human mutations will be of the utmost
importance in uncovering the neural and molecular bases of
ASD and to pave the way for clinical trials of treatments for
core social domains. A homogeneous group of ASD individu-
als with phenotype and synaptic defects should be enrolled in
pharmacological trials to test the efficacy and the safety of spe-
cific compounds. These trials would measure outcomes in the
core social domain of ASD and also identify specific biomark-
ers for a wider perspective of treatment outcomes. Investigations
of dynamic brain changes in ASD patients, using fMRI after
treatments, would be extremely valuable in order to shed light
on the neural underpinnings of core social impairment in these
individuals.
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